Gapping up
In reaction to strong earnings/guidance: SHLD +4.2%, .
M&A news: DATE +3.6% (announces the receipt of an amended 'going private' proposal for $4.80/share or $7.20/ADS share, also reported earnings)
Other news: BLDP +13.3% (announces a $10 million deal to power 33 clean energy buses in China), FCSC +9.7% (and Intrexon (XON) announce positive in vitro pre-clinical data for FCX-007 to treat Recessive Dystrophic Epidermolysis Bullosa), PTBI +9.2% (licensed an AAV gene therapy for the treatment of Juvenile Batten disease from UNeMed ), MXL +8.3% (Soros Fund Mgmt disclosed 5.19% passive stake), DB +6% (appoints John Cryan as Co-CEO effective July 1, suceeding Jürgen Fitschen and Anshu Jain, also, upgraded to Neutral from Underperform at BofA/Merrill), VISN +5.3% (awarded exclusive concession contracts, to install and operate its on-bus free Wi-Fi network on 5K urban buses in Hangzhou city), AOSL +3% (commences $30 mln Modified Dutch Auction tender offer for its common shares), PANW +1.4% (China considering options to protect against hackers and may attempt to require foreign tech firms to disclose source coding), RAD +1.2% (favorable commentary on Friday's Mad Money), SUNE +0.9% (awarded an additional five solar photovoltaic projects in South Africa, totaling 371 MW)
Analyst comments: DSX +8% (positive Deutsche Bank comments and target raise to $10.50), GLPG +7.1% (initiated with a Overweight at Morgan Stanley), PQ +6.4% (upgraded to Outperform from Mkt Perform at Raymond James), INVN +1% (upgraded to Outperform from Market Perform at Northland Capital), TSLA +0.8% (target raised to $335 from $275 at Robert W. Baird),WMT +0.5% (upgraded to Strong Buy from Outperform at Raymond James)
In reaction to strong earnings/guidance: SHLD +4.2%, .
M&A news: DATE +3.6% (announces the receipt of an amended 'going private' proposal for $4.80/share or $7.20/ADS share, also reported earnings)
Other news: BLDP +13.3% (announces a $10 million deal to power 33 clean energy buses in China), FCSC +9.7% (and Intrexon (XON) announce positive in vitro pre-clinical data for FCX-007 to treat Recessive Dystrophic Epidermolysis Bullosa), PTBI +9.2% (licensed an AAV gene therapy for the treatment of Juvenile Batten disease from UNeMed ), MXL +8.3% (Soros Fund Mgmt disclosed 5.19% passive stake), DB +6% (appoints John Cryan as Co-CEO effective July 1, suceeding Jürgen Fitschen and Anshu Jain, also, upgraded to Neutral from Underperform at BofA/Merrill), VISN +5.3% (awarded exclusive concession contracts, to install and operate its on-bus free Wi-Fi network on 5K urban buses in Hangzhou city), AOSL +3% (commences $30 mln Modified Dutch Auction tender offer for its common shares), PANW +1.4% (China considering options to protect against hackers and may attempt to require foreign tech firms to disclose source coding), RAD +1.2% (favorable commentary on Friday's Mad Money), SUNE +0.9% (awarded an additional five solar photovoltaic projects in South Africa, totaling 371 MW)
Analyst comments: DSX +8% (positive Deutsche Bank comments and target raise to $10.50), GLPG +7.1% (initiated with a Overweight at Morgan Stanley), PQ +6.4% (upgraded to Outperform from Mkt Perform at Raymond James), INVN +1% (upgraded to Outperform from Market Perform at Northland Capital), TSLA +0.8% (target raised to $335 from $275 at Robert W. Baird),WMT +0.5% (upgraded to Strong Buy from Outperform at Raymond James)